Viridian Therapeutics, Inc. VRDN Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $141K+95.8% | $132K+83.3% | $70.57M+81,958% | $75K+4.2% | $72K0.0% | ||
| $77.63M+1.0% | $89.21M+24.0% | $86.26M+24.7% | $86.63M+54.2% | $76.84M+87.7% | ||
| $38.68M+126% | —— | —— | —— | $17.1M+12.0% | ||
| $116.31M+23.8% | $122.88M+40.4% | $110.58M+32.3% | $106.84M+47.9% | $93.94M+67.8% | ||
| -$116.17M-23.8% | -$122.75M-40.3% | -$40.01M+52.1% | -$106.77M-47.9% | -$93.87M-67.9% | ||
| -82,389.4%+47,980pp | -92,991.7%+28,497pp | -56.7%+97,013pp | -142,356%-42,096pp | -130,369.4%-52,735pp | ||
| $3.46M+529% | $3.28M+535% | $560K+5.9% | $514K-13.9% | $550K-6.3% | ||
| $7.87M+4.4% | $7.79M-8.5% | $5.52M-26.5% | $6.55M-16.0% | $7.54M-5.1% | ||
| $11.27M+62.0% | $2.39M-69.1% | $5.41M-20.3% | $6.03M-16.2% | $6.95M-5.5% | ||
| -$104.9M-20.7% | -$120.36M-51.0% | -$34.6M+54.9% | -$100.74M-55.0% | -$86.91M-79.0% | ||
| -74,397.9%+46,313pp | -91,178%+19,551pp | -49%+89,124pp | -134,313.3%-44,045pp | -120,711.1%-53,292pp | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | 81.3M+33.1% | ||
| —— | —— | —— | —— | —— | ||
| -$105.91M-22.2% | -$120.27M-49.1% | -$34.31M+54.4% | -$100.91M-54.8% | -$86.66M-76.0% | ||
| $7.53M— | —— | —— | —— | $0— | ||
| -$1.01M-495% | $84K+109% | $294K-80.1% | -$176K0.0% | $255K+136% | ||
| -$672K-1,767% | -$2.12M-727% | $453K+332% | $0— | -$36K— | ||
| $77.63M+1.0% | $89.21M+24.0% | $86.26M+24.7% | $86.63M+54.2% | $76.84M+87.7% | ||
| -$116.17M-23.8% | -$122.75M-40.3% | -$40.01M+52.1% | -$106.77M-47.9% | -$93.87M-67.9% | ||
| -$116.05M-23.8% | -$122.63M-40.4% | -$39.9M+52.1% | -$106.65M-48.0% | -$93.75M-68.2% | ||
| -$116.05M-23.8% | -$122.63M-40.4% | -$39.9M+52.1% | -$106.65M-48.0% | -$93.75M-68.2% | ||
| -82,303.5%+47,903pp | -92,900.8%+28,417pp | -56.5%+96,862pp | -142,205.3%-42,143pp | -130,206.9%-52,774pp | ||
| -$116.17M-23.8% | -$122.75M-40.3% | -$40.01M+52.1% | -$106.77M-47.9% | -$93.87M-67.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Viridian Therapeutics, Inc.'s profit margins?
- Gross margin is 36.3% and operating margin is -543.9%, with a -508.5% net margin.
- Where does Viridian Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Viridian Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.